Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Gandhy SU, Karzai FH, Bilusic M, McMahon S, Cordes LM, Marte J, Weisman AJ, Perk TG, Lindenberg L, Mena E, Turkbey B, Arlen PM, Dahut WL, Figg WD, Choyke P, Gulley JL, Madan RA. Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide. Eur Urol Oncol. 2024 Aug;7(4):735-741. doi: 10.1016/j.euo.2023.09.010. Epub 2023 Oct 17. PubMed PMID: 37858437; PubMed Central PMCID: PMC11021375.
Choradia N, Karzai F, Nipp R, Naqash AR, Gulley JL, Floudas CS. Increasing diversity in clinical trials: demographic trends at the National Cancer Institute, 2005-2020. J Natl Cancer Inst. 2024 Jul 1;116(7):1063-1071. doi: 10.1093/jnci/djae018. PubMed PMID: 38374401; PubMed Central PMCID: PMC11223850.
Belue MJ, Harmon SA, Yang D, An JY, Gaur S, Law YM, Turkbey E, Xu Z, Tetreault J, Lay NS, Yilmaz EC, Phelps TE, Simon B, Lindenberg L, Mena E, Pinto PA, Bagci U, Wood BJ, Citrin DE, Dahut WL, Madan RA, Gulley JL, Xu D, Choyke PL, Turkbey B. Deep Learning-Based Detection and Classification of Bone Lesions on Staging Computed Tomography in Prostate Cancer: A Development Study. Acad Radiol. 2024 Jun;31(6):2424-2433. doi: 10.1016/j.acra.2024.01.009. Epub 2024 Jan 22. PubMed PMID: 38262813; PubMed Central PMCID: PMC11214604.
Xue E, Bracken-Clarke D, Iannantuono GM, Choo-Wosoba H, Gulley JL, Floudas CS. Utility of Large Language Models for Health Care Professionals and Patients in Navigating Hematopoietic Stem Cell Transplantation: Comparison of the Performance of ChatGPT-3.5, ChatGPT-4, and Bard. J Med Internet Res. 2024 May 17;26:e54758. doi: 10.2196/54758. PubMed PMID: 38758582; PubMed Central PMCID: PMC11143389.
Ma KC, Mena E, Lindenberg L, Lay NS, Eclarinal P, Citrin DE, Pinto PA, Wood BJ, Dahut WL, Gulley JL, Madan RA, Choyke PL, Turkbey IB, Harmon SA. Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN. Oncotarget. 2024 May 7;15:288-300. doi: 10.18632/oncotarget.28583. PubMed PMID: 38712741; PubMed Central PMCID: PMC11075367.
Iannantuono GM, Bracken-Clarke D, Karzai F, Choo-Wosoba H, Gulley JL, Floudas CS. Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study. Oncologist. 2024 May 3;29(5):407-414. doi: 10.1093/oncolo/oyae009. PubMed PMID: 38309720; PubMed Central PMCID: PMC11067804.
Lopez DC, Fabian KP, Padget MR, Robbins YL, Kowalczyk JT, Lassoued W, Pastor DM, Allen CT, Gallia GL, Gulley JL, Hodge JW, London NR Jr. Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence. Front Oncol. 2024;14:1376622. doi: 10.3389/fonc.2024.1376622. eCollection 2024. PubMed PMID: 38741774; PubMed Central PMCID: PMC11089222.
Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X, Clavel A, Reyes-Gonzalez JM, Dyomin V, Diaz L, Zhang L, Abbas S, Sun M, Hsieh CM, Ho M, Shern JF, Gulley JL, Hinrichs CS. Cooperative Armoring of CAR and TCR T Cells by T Cell-Restricted IL15 and IL21 Universally Enhances Solid Tumor Efficacy. Clin Cancer Res. 2024 Apr 15;30(8):1555-1566. doi: 10.1158/1078-0432.CCR-23-1872. PubMed PMID: 37910044; PubMed Central PMCID: PMC11018485.
Rajan A, Abdul Sater H, Rahma O, Agajanian R, Lassoued W, Marté JL, Tsai YT, Donahue RN, Lamping E, Bailey S, Weisman A, Walter-Rodriguez B, Ito R, Vugmeyster Y, Sato M, Machl A, Schlom J, Gulley JL. Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer. J Immunother Cancer. 2024 Mar 13;12(3). doi: 10.1136/jitc-2023-008480. PubMed PMID: 38485188; PubMed Central PMCID: PMC10941133.
Minnar CM, Lui G, Gulley JL, Schlom J, Gameiro SR. Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine. Front Oncol. 2023;13:1321318. doi: 10.3389/fonc.2023.1321318. eCollection 2023. PubMed PMID: 38260854; PubMed Central PMCID: PMC10802843.
Lawler M, Sullivan R, Abou-Alfa GK, McCloskey K, Keatley D, Feighan J, Dahut W, Mulroe E, Ladner R, Genead M, Lowery M, Gulley JL, Scott CJ, Longley DB, Culhane A, Gallagher WM, Orr N, Chanock SJ, Gopal S. Health diplomacy in action: The cancer legacy of the Good Friday Agreement. J Cancer Policy. 2023 Dec;38:100448. doi: 10.1016/j.jcpo.2023.100448. Epub 2023 Oct 14. PubMed PMID: 37839622.
Hsu J, Donahue RN, Katragadda M, Lowry J, Huang W, Srinivasan K, Guntas G, Tang J, Servattalab R, Moisan J, Tsai YT, Stoop A, Palakurthi S, Chopra R, Liu K, Wherry EJ, Su Z, Gulley JL, Bayliffe A, Schlom J. A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity. Sci Transl Med. 2023 Nov 29;15(724):eadi0258. doi: 10.1126/scitranslmed.adi0258. Epub 2023 Nov 29. PubMed PMID: 38019931.
Iannantuono GM, Chandran E, Floudas CS, Choo-Wosoba H, Butera G, Roselli M, Gulley JL, Karzai F. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials. Cancer Treat Rev. 2023 Nov;120:102623. doi: 10.1016/j.ctrv.2023.102623. Epub 2023 Sep 9. Review. PubMed PMID: 37716332; PubMed Central PMCID: PMC10591840.
Iannantuono GM, Bracken-Clarke D, Karzai F, Choo-Wosoba H, Gulley JL, Floudas CS. Comparison of Large Language Models in Answering Immuno-Oncology Questions: A Cross-Sectional Study. medRxiv. 2023 Oct 31;. doi: 10.1101/2023.10.31.23297825. PubMed PMID: 38076813; PubMed Central PMCID: PMC10705618.
Hoang DT, Dinstag G, Hermida LC, Ben-Zvi DS, Elis E, Caley K, Sammut SJ, Sinha S, Sinha N, Dampier CH, Stossel C, Patil T, Rajan A, Lassoued W, Strauss J, Bailey S, Allen C, Redman J, Beker T, Jiang P, Golan T, Wilkinson S, Sowalsky AG, Pine SR, Caldas C, Gulley JL, Aldape K, Aharonov R, Stone EA, Ruppin E. Prediction of cancer treatment response from histopathology images through imputed transcriptomics. Res Sq. 2023 Sep 15;. doi: 10.21203/ PubMed PMID: 37790315; PubMed Central PMCID: PMC10543028.
Redman JM, O'Sullivan Coyne G, Reed CT, Madan RA, Strauss J, Steinberg SJ, Marté J, Cordes L, Heery C, Gulley JL. Avelumab in Patients With Metastatic Colorectal Cancer. Oncologist. 2023 Sep 7;28(9):823-e804. doi: 10.1093/oncolo/oyad162. PubMed PMID: 37310790; PubMed Central PMCID: PMC10485289.
Iannantuono GM, Bracken-Clarke D, Floudas CS, Roselli M, Gulley JL, Karzai F. Applications of large language models in cancer care: current evidence and future perspectives. Front Oncol. 2023;13:1268915. doi: 10.3389/fonc.2023.1268915. eCollection 2023. Review. PubMed PMID: 37731643; PubMed Central PMCID: PMC10507617.
Madan RA, Bilusic M, Stein MN, Donahue RN, Arlen PM, Karzai F, Plimack E, Wong YN, Geynisman DM, Zibelman M, Mayer T, Strauss J, Chen G, Rauckhorst M, McMahon S, Couvillon A, Steinberg S, Figg WD, Dahut WL, Schlom J, Gulley JL. Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. Oncologist. 2023 Jul 5;28(7):642-e561. doi: 10.1093/oncolo/oyad058. PubMed PMID: 37134294; PubMed Central PMCID: PMC10322134.
John L, Smith H, Ilanchezhian M, Lockridge R, Reilly KM, Raygada M, Dombi E, Sandler A, Thomas BJ, Glod J, Miettinen M, Allen T, Sommer J, Levy J, Lozinsky S, Dix D, Bouffet E, MacDonald S, Mukherjee D, Snyderman CH, Rowan NR, Malyapa R, Park DM, Heery C, Gardner PA, Cote GM, Fuller S, Butman JA, Jackson S, Gulley JL, Widemann BC, Wedekind MF. The NIH pediatric/young adult chordoma clinic and natural history study: Making advances in a very rare tumor. Pediatr Blood Cancer. 2023 Jun 22;:e30358. doi: 10.1002/pbc.30358. [Epub ahead of print] PubMed PMID: 37347686; PubMed Central PMCID: PMC10739575.
Chang R, Gulley JL, Fong L. Vaccinating against cancer: getting to prime time. J Immunother Cancer. 2023 Jun;11(6). doi: 10.1136/jitc-2022-006628. Review. PubMed PMID: 37286302; PubMed Central PMCID: PMC10254974.
Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL, Turkbey E, Mydlarz W, Joshi A, London NR Jr, Pierce M, Taylor R, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. J Clin Invest. 2023 Jun 1;133(11). doi: 10.1172/JCI172059. PubMed PMID: 37259923; PubMed Central PMCID: PMC10231984.
Koti M, Bivalacqua T, Black PC, Cathomen T, Galsky MD, Gulley JL, Ingersoll MA, Kamat AM, Kassouf W, Siemens DR, Gao J. Adaptive Immunity in Genitourinary Cancers. Eur Urol Oncol. 2023 Jun;6(3):263-272. doi: 10.1016/j.euo.2023.03.002. Epub 2023 Apr 15. Review. PubMed PMID: 37069029.
Peer CJ, Schmidt KT, Arisa O, Richardson WJ, Paydary K, Goldstein DA, Gulley JL, Figg WD, Ratain MJ. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation. J Clin Pharmacol. 2023 Jun;63(6):672-680. doi: 10.1002/jcph.2203. Epub 2023 Feb 8. PubMed PMID: 36624662; PubMed Central PMCID: PMC10175103.
Barcellos-Hoff MH, Gulley JL. Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy. Clin Cancer Res. 2023 Jun 1;29(11):2025-2033. doi: 10.1158/1078-0432.CCR-21-3750. PubMed PMID: 36598437; PubMed Central PMCID: PMC10238558.
Zhang L, Troccoli CI, Mateo-Victoriano B, Lincheta LM, Jackson E, Shu P, Plastini T, Tao W, Kwon D, Chen X, Sharma J, Jorda M, Gulley JL, Bilusic M, Lockhart AC, Beuve A, Rai P. The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance. bioRxiv. 2023 May 3;. doi: 10.1101/2023.05.03.537252. PubMed PMID: 37205442; PubMed Central PMCID: PMC10187243.
Strauss J, Deville JL, Sznol M, Ravaud A, Maruzzo M, Pachynski RK, Gourdin TS, Maio M, Dirix L, Schlom J, Donahue RN, Tsai YT, Wang X, Vugmeyster Y, Beier F, Seebeck J, Schroeder A, Chennoufi S, Gulley JL. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2022-005813. PubMed PMID: 37236636; PubMed Central PMCID: PMC10230972.
Madan RA, Redman JM, Karzai F, Dahut WL, Cordes L, Fakhrejahani F, Vu T, Sheikh N, Schlom J, Gulley JL. Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine. J Immunother. 2023 May 1;46(4):145-151. doi: 10.1097/CJI.0000000000000459. Epub 2023 Feb 24. PubMed PMID: 36821354; PubMed Central PMCID: PMC10072211.
Parsons JK, Pinto PA, Pavlovich CP, Uchio E, Nguyen MN, Kim HL, Gulley JL, Sater HA, Jamieson C, Hsu CH, Wojtowicz M, House M, Schlom J, Donahue RN, Dahut WL, Madan RA, Bailey S, Centuori S, Bauman JE, Parnes HL, Chow HS. A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance. Eur Urol Focus. 2023 May;9(3):447-454. doi: 10.1016/j.euf.2022.12.002. Epub 2022 Dec 12. PubMed PMID: 36517408; PubMed Central PMCID: PMC10258223.
Gatti-Mays ME, Tschernia NP, Strauss J, Madan RA, Karzai FH, Bilusic M, Redman J, Sater HA, Floudas CS, Toney NJ, Donahue RN, Jochems C, Marté JL, Francis D, McMahon S, Lamping E, Cordes L, Schlom J, Gulley JL. A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors. Oncologist. 2023 Apr 6;28(4):364-e217. doi: 10.1093/oncolo/oyac244. PubMed PMID: 36640137; PubMed Central PMCID: PMC10078919.
Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J, Jerusalem G, Penel N, Saada-Bouzid E, Garrido P, Helwig C, Locke G, Ojalvo LS, Gulley JL. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. Oncologist. 2023 Mar 17;28(3):258-267. doi: 10.1093/oncolo/oyac253. PubMed PMID: 36571770; PubMed Central PMCID: PMC10020814.
Toney NJ, Gatti-Mays ME, Tschernia NP, Strauss J, Gulley JL, Schlom J, Donahue RN. Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12. Int Immunopharmacol. 2023 Mar;116. doi: 10.1016/j.intimp.2023.109736. Epub 2023 Feb 16. PubMed PMID: 37234190; PubMed Central PMCID: PMC10208359.
Atkins MB, Ascierto PA, Feltquate D, Gulley JL, Johnson DB, Khushalani NI, Sosman J, Yap TA, Kluger H, Sullivan RJ, Tawbi H. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies. J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-005923. PubMed PMID: 36918225; PubMed Central PMCID: PMC10016252.
Robbins Y, Friedman J, Redman J, Sievers C, Lassoued W, Gulley JL, Allen CT. Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer. Oral Oncol. 2023 Mar;138:106309. doi: 10.1016/j.oraloncology.2023.106309. Epub 2023 Jan 20. PubMed PMID: 36682187; PubMed Central PMCID: PMC9974754.
Phelps TE, Harmon SA, Mena E, Lindenberg L, Shih JH, Citrin DE, Pinto PA, Wood BJ, Dahut WL, Gulley JL, Madan RA, Choyke PL, Turkbey B. Predicting Outcomes of Indeterminate Bone Lesions on (18)F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer. J Nucl Med. 2023 Mar;64(3):395-401. doi: 10.2967/jnumed.122.264334. Epub 2022 Oct 20. PubMed PMID: 36265908.
Spira A, Wertheim MS, Kim EJ, Tan B, Lenz HJ, Nikolinakos P, Rich PL, Jehl G, Machl A, Ito R, Gulley JL, Kopetz S. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial. Oncologist. 2023 Feb 8;28(2):e124-e127. doi: 10.1093/oncolo/oyac254. PubMed PMID: 36576431; PubMed Central PMCID: PMC9907041.
Rajan A, Gray JE, Devarakonda S, Birhiray R, Korchin B, Menius E, Donahue RN, Schlom J, Gulley JL. Phase 1 trial of CV301 in combination with anti-PD-1 therapy in nonsquamous non-small cell lung cancer. Int J Cancer. 2023 Feb 1;152(3):447-457. doi: 10.1002/ijc.34267. Epub 2022 Sep 9. PubMed PMID: 36054490; PubMed Central PMCID: PMC10690498.
Hansen ME, Mangusan R, Lurain K, Odeny T, George J, Lu C, Manion M, Widell A, Ekwede I, Whitby D, Gulley JL, Kadri SS, Elinoff JM, Barochia A, Torabi-Parizi P, Uldrick TS, Yarchoan R, Ramaswami R. Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases. AIDS. 2022 Nov 15;36(14):1969-1978. doi: 10.1097/QAD.0000000000003333. Epub 2022 Jul 16. PubMed PMID: 35848586; PubMed Central PMCID: PMC9617765.
Lopez DC, Robbins YL, Kowalczyk JT, Lassoued W, Gulley JL, Miettinen MM, Gallia GL, Allen CT, Hodge JW, London NR Jr. Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies. Front Oncol. 2022;12:1012058. doi: 10.3389/fonc.2022.1012058. eCollection 2022. PubMed PMID: 36338744; PubMed Central PMCID: PMC9634172.
Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL, Turkbey E, Mydlarz W, Joshi A, London NR Jr, Pierce M, Taylor R, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT. Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer. J Clin Invest. 2022 Sep 15;132(18). doi: 10.1172/JCI161400. PubMed PMID: 35727629; PubMed Central PMCID: PMC9479764.
Schmidt KT, Karzai F, Bilusic M, Cordes LM, Chau CH, Peer CJ, Wroblewski S, Huitema ADR, Schellens JHM, Gulley JL, Dahut WL, Figg WD, Madan RA. A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide. Oncologist. 2022 Sep 2;27(9):718-e694. doi: 10.1093/oncolo/oyac100. PubMed PMID: 35640474; PubMed Central PMCID: PMC9438911.
Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M. Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005413. PubMed PMID: 36175037; PubMed Central PMCID: PMC9528604.
Odeny TA, Lurain K, Strauss J, Fling SP, Sharon E, Wright A, Martinez-Picado J, Moran T, Gulley JL, Gonzalez-Cao M, Uldrick TS, Yarchoan R, Ramaswami R. Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. J Immunother Cancer. 2022 Sep;10(9). doi: 10.1136/jitc-2022-005128. PubMed PMID: 37935055; PubMed Central PMCID: PMC9442492.
Liang H, Jo JH, Zhang Z, MacGibeny MA, Han J, Proctor DM, Taylor ME, Che Y, Juneau P, Apolo AB, McCulloch JA, Davar D, Zarour HM, Dzutsev AK, Brownell I, Trinchieri G, Gulley JL, Kong HH. Predicting cancer immunotherapy response from gut microbiomes using machine learning models. Oncotarget. 2022;13:876-889. doi: 10.18632/oncotarget.28252. eCollection 2022. PubMed PMID: 35875611; PubMed Central PMCID: PMC9295706.
Davies JS, Karimipour F, Zhang L, Nagarsheth N, Norberg S, Serna C, Strauss J, Chiou S, Gulley JL, Hinrichs CS. Non-synergy of PD-1 blockade with T-cell therapy in solid tumors. J Immunother Cancer. 2022 Jul;10(7). doi: 10.1136/jitc-2022-004906. PubMed PMID: 35793866; PubMed Central PMCID: PMC9260838.
Gameiro SR, Strauss J, Gulley JL, Schlom J. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status. Exp Biol Med (Maywood). 2022 Jul;247(13):1124-1134. doi: 10.1177/15353702221089910. Epub 2022 Apr 27. Review. PubMed PMID: 35473390; PubMed Central PMCID: PMC9335510.
Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Mol Oncol. 2022 Jun;16(11):2117-2134. doi: 10.1002/1878-0261.13146. Epub 2022 Jan 4. Review. PubMed PMID: 34854206; PubMed Central PMCID: PMC9168966.
Fourquet A, Rosenberg A, Mena E, Shih JJ, Turkbey B, Blain M, Bergvall E, Lin F, Adler S, Lim I, Madan RA, Karzai F, Gulley JL, Dahut WL, Wood BJ, Chang R, Levy E, Choyke PL, Lindenberg L. A Comparison of (18)F-DCFPyL, (18)F-NaF, and (18)F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer. J Nucl Med. 2022 May;63(5):735-741. doi: 10.2967/jnumed.121.262371. Epub 2021 Sep 2. PubMed PMID: 34475237.
Romero PJ, Gulley JL, Hwu P, Dean M, Million-Weaver S. Celebrating a decade of the Journal for ImmunoTherapy of Cancer. J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-005207. PubMed PMID: 35618287; PubMed Central PMCID: PMC9125750.
Mullenix C, Ballman M, Chen H, Swift S, McAdams MJ, Tsai YT, Donahue RN, Poretta T, Gupta S, Loehrer PJ, Schlom J, Gulley JL, Rajan A. Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors. Oncologist. 2022 Apr 5;27(4):e353-e356. doi: 10.1093/oncolo/oyac026. PubMed PMID: 35380721; PubMed Central PMCID: PMC8982432.
Hrinczenko B, Iannotti N, Goel S, Spigel D, Safran H, Taylor MH, Bennouna J, Wong DJ, Kelly K, Verschraegen C, Bajars M, Manitz J, Ruisi M, Gulley JL. Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor. Future Oncol. 2022 Apr;18(11):1333-1342. doi: 10.2217/fon-2021-0930. Epub 2022 Feb 11. PubMed PMID: 35144482; PubMed Central PMCID: PMC9066292.
What would you like to do?